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1. Introduction
The frameless FibroplantTM-levonorgestrel (LNG)
intrauterine system (IUS) is an anchored levonorgestrel-
releasing device releasing approximately 14 lg of LNG
per day. The system is eﬀective for at least three years.
The anchor is implanted into the myometrium of the
uterine fundus using an insertion instrument. The LNG
IUS is frameless, completely ﬂexible and adapts to
cavities of every size and shape. Clinical experience with
the system in peri- and post-menopausal women has
been published previously in [1,2].
2. Patients and methods
Sixty-two post-menopausal women using continu-
ous oestrogen (percutaneous 17 oestradiol, 1.5 mg
daily, or an equivalent dose by patch or oral oestro-
gen) combined with the frameless intrauterine LNG
were evaluated. After having used the regimen for a
minimum period of three years, they were examined
by transvaginal ultrasound examination (TVU) (Ul-
tramark 4Plus, ATL Inc., USA) and endometrial
biopsy (Probet, Gynetics, Belgium) in order to assess
endometrial safety. The use of the LNG IUS was
approved by the Ethics Committee of the University
in Ghent, Belgium, and written informed consent was
obtained. All women were screened according to the
World Health Organisation (WHO) eligibility criteria
prior to entering the study. The thickness of the en-
dometrium at baseline, assessed according to the
measures used by Fleischer et al. [3], showed a thin
endometrium (<5 mm) at the start of the study in all
women. The endometrial samples were drawn from all
parts of the uterus to get a representative sample.
Biopsies were placed in phosphate-buﬀered formalde-
hyde (4%) immediately upon collection and stained
with haematoxylin and eosin for examination. They
were examined by two independent pathologists, who
did not have any knowledge about the study, ac-
cording to the diagnostic categories set by Hendrick-
son and Kempson [4].
3. Results
Histological examinations were conducted in 62 post-
menopausal women after an average period of use of the
method of 43 months (range 36–50 months). They
showed predominantly inactive endometrium charac-
terised by pseudodecidual reaction of the endometrial
stroma with endometrial atrophia. There were no spec-
imens showing signs of proliferation. At follow-up, a
thin endometrium (<5 mm in thickness), as assessed by
transvaginal ultrasound, was found in all post-meno-
pausal women in this study.
4. Discussion
In the 62 women in our study, no hyperplasia was
detected. A similar low incidence (0%) of hyperplasia in
post-menopausal women receiving estrogen therapy
(ET) and a low-dose LNG IUS has been observed in
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other studies [5]. Intrauterine progestogen delivery,
particularly LNG, is probably more eﬀective in post-
menopausal women in preventing endometrial prolifer-
ation than oral treatment because of the uniform sup-
pression of the endometrium throughout the whole
thickness of the mucosa caused by the high tissue con-
centrations when the hormone is applied locally [6].
However, with sequential therapy, there may be a higher
rate of hyperplasia, including complex and atypical hy-
perplasia [7]. As far as prevention of endometrial hy-
perplasia is concerned, the duration of the progestogen
administration seems more important than the daily
dose [8]. The promising results in this study suggest that
continuous, intrauterine progestogen delivery could be
ideal.
TVU, conducted in all subjects in this study ap-
peared to correlate well with the histological ﬁndings.
This corresponds with previous studies that found a
good correlation if the endometrium is thin (4 or 5
mm) [9].
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